We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS MOVES TO DISCONTINUE SERZONE, IMPACT ON GENERICS UNKNOWN
BMS MOVES TO DISCONTINUE SERZONE, IMPACT ON GENERICS UNKNOWN
May 24, 2004
Generic-drug industry observers see mixed opportunities in Bristol-Myers Squibb’s (BMS’) recent decision to stop marketing its antidepressant Serzone (nefazodone HCl) — a decision that will give generics 100 percent market share of a former top-selling product now facing safety concerns.